Search results for: Precision Medicine
Filter search results
Plan For A New EU Pharmaceutical Legislation: What Will It Mean For Pharmaceutical Innovation?
12 April 2024
…Intellectual Property. [online] Available at: https://www.efpia.eu/about-medicines/development-of-medicines/intellectual-property/ [Accessed 11 Apr. 2024]. European Medicines Agency and Sonia Ribeiro, 2018. Data exclusivity, market protection, orphan and paediatric rewards. [online] Available at: https://www.ema.europa.eu/en/documents/presentation/presentation-data-exclusivity-market-protection-orphan-and-paediatric-rewards-s-ribeiro_en.pdf [Accessed 5 Apr. 2024]. European…
Reflections from Adrian Towse on decades of HEOR research and impact
11 November 2025
…whilst a value-based price is established. Much of this work has been with Lou Garrison and it links to work on the economics of precision medicine, including the challenges of…
Forecasting the Challenges and Economics of Drug Development in 2022
9 July 2013
…this publication. 1. Health care will be radically transformed as “precision” medicines plug into the specific genetic makeup of both patients and diseases, paired with increasingly powerful and convenient diagnostics….
Global rare‑disease policy shifts: what are the implications for equitable access to orphan medicines?
1 March 2026
…as many orphan medicines compared with the EMA. One potential explanation for this divergence is the EU’s more restricted incentive offer, in addition to the European Medicines Agency (EMA) necessitating…
The Importance of Diversity of Supply in Rare Diseases Markets
23 January 2025
…RD medicine markets enhance healthcare system resilience and drive pharmaceutical innovation in areas of high unmet need and societal value. While medicine shortages are widely recognized as a critical issue…
International Comparison of Medicines Usage: Quantitative Analysis from a Swedish Perspective
1 May 2015
…different classes of medicines. In a majority of classes usage is below the two international averages. But while, for example, usage of cardiovascular medicines is low by international standards, use…
Lung Cancer’s Biggest Test: How Can We Mobilise NGS Testing to Transform Lung Cancer Care?
7 December 2023, 12:00am
…access to personalized medicines and combination medicines. She has expertise in market access and HTA, leading multiple submissions to NICE and the Scottish Medicines Consortium. Professor Mike Drummond | Professor…
Meeting the Challenges of Drug Development in 2022: Summary of OHE’s 50th Anniversary Conference
11 October 2012
…practical application after approval as well, as personalised medicine (also called “stratified” or “precision” medicine) enhances the prospects for treating patients more effectively and safely. At the same time, however, many diseases with…
OHE Develops New, Bottom-Up Model for Forecasting UK Medicines Expenditure
3 April 2013
Medicines account for less than 10% of total NHS expenditure in the UK. Because spending on medicines is easy to separate out, however, this sector continues to come under particular…